Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022
12/02/2022 - 09:31 AM
- Includes oral presentation for 1.5 mg/kg cold urticaria cohort -
- Company to host webcast conference call on Tuesday, December 6 at 8:00 am ET -
HAMPTON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple presentations from the barzolvolimab development program will be presented at the 6th GA2 LEN Global Urticaria Forum (GUF) being held December 7-8 in Berlin, Germany. Abstracts will be available on the meeting website on December 6th .
Presentations at GUF 2022 are outlined below and include new data from both the Phase 1b 1.5 mg/kg cohort conducted in cold urticaria and long term follow data from the Phase 1b 3.0 mg/kg cohorts conducted in cold urticaria and symptomatic dermographism. The chronic spontaneous urticaria (CSU) and wound healing presentations are Encore presentations and do not include new data. WEDNESDAY, December 7, 2022
Oral: “Cold urticaria patients achieve complete response with 1.5 mg/kg barzolvolimab” - Session III: Urticaria treatments and predictors of response | 18:07-18:16 CET THURSDAY, December 8, 2022
Poster: “Barzolvolimab-induced response and mast cell suppression are durable and linked” | 10:00 to 11:10 CET ENCORE Oral: “Multi-dosed barzolvolimab is effective in chronic spontaneous urticaria” - Session IV: Treatment of urticaria | 09:05-09:14 CET ENCORE Poster: Mast cell reduction does not impair human cutaneous wound healing Webcast and Conference Call The Company will host a conference call/webcast to discuss the data at 8:00 a.m. ET on Tuesday, December 6. The event will be webcast live and can be accessed by going to the "Events & Presentations" page under the "Investors & Media” section of the Celldex Therapeutics website at www.celldex.com .
About Celldex Therapeutics, Inc. Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com .
Company Contact Sarah Cavanaugh Senior Vice President, Corporate Affairs & Administration (508) 864-8337scavanaugh@celldex.com
Patrick Till Meru Advisors (484) 788-8560ptill@meru.com
Celldex Therapeutics Inc.
CLDX Rankings
#4135 Ranked by Stock Gains
CLDX Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Medical Specialties, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Hampton
About CLDX
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im